Clinical trial tests herpes virus-based therapy for neurogenic bladder in people with spinal cord injury

A modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder in people with spinal cord injury is underway in a first-in-human clinical trial by UTHealth Houston at TIRR Memorial Hermann.

Mountain town confronts an unexpected public health catastrophe

Before Hurricane Helene, had you stopped by one of the many breweries, art galleries, or award-winning restaurants in Asheville, North Carolina, and spoken with anyone

October 18, 2024

Danish biotech gears up for Phase IIb hidradenitis suppurativa trial following early clinical results

MC2 Therapeutics’ drug candidate for hidradenitis suppurativa has shown hints of efficacy potential in a Phase IIa trial, sparking plans for Phase IIb development with

October 12, 2023

Soleno Therapeutics’ ‘life-changing’ drug nears approval decision

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I can’t stop

March 13, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.